Zila's OraTest Product Available in Belgium and Luxembourg From MEDIPLUS

LONDON (PROTEXT) - Zila Europe, a division of Zila, Inc.(Nasdaq: ZILA), international provider of healthcare products fordental/medical professionals and consumers, announced theintroduction of the OraTest(R) oral cancer diagnostic product inBelgium and Luxembourg. The product is available from MEDIPLUS, aBelgian company distributing dental products to dentists andhospital-based clinicians in Belgium and Luxembourg. MEDIPLUS canbe reached at 02 653 88 18, fax 02 654 20 03. Oral cancer symposiums organized by national dentalassociations are being held in Luxembourg on September 22, andBelgium on September 23 and 25. Leading oral cancer specialistsfrom the region's hospitals and dental schools are presenting thecase for dentists to screen all patients annually for oralcancer. Practitioners are being warned to be especially vigilantwith those most at risk, namely patients who are over forty anduse tobacco (in any form) and/or drink heavily. Joining the experts is Dr. Gerald Feaver, a United Kingdomauthority on oral cancer screening and the use of the OraTestproduct. Zila's product is the world's first oral cancerdetection aid to be used in conjunction with a full head, neckand soft tissue examination on patients at risk. A simple,reliable sequence of three rinse solutions, OraTest isadministered chairside in a 5-10 minute procedure. Any suspiciouslesions are confirmed by repeating the test 10-14 days later. Asecond stain in the same area requires referral to a hospitalspecialist. The OraTest product is designed to detect difficult-to-observe, asymptomatic, early-stage cancerous lesions. According to medical literature, when oral cancer is detectedat advanced stage, 5-year survival rates are as low as 18percent. But with early detection, survival rates exceed 90percent. In Luxembourg and Belgium, more than 400 people arediagnosed with oral cancer each year. Worldwide, nearly 900,000new cases of oral cancer occurred in 1996; incidence andmortality rates are rising. The OraTest product is now available or approved in 14countries; additional regulatory approvals and distributionagreements are being pursued in many countries worldwide. In theUK and Australia, the product is marketed as OraScreen(TM).Additional OraTest product marketing launches are planned inEurope and the Middle East in the coming months. In the United States, Douglas Burkett, Ph.D., President ofZila Manufacturing, noted that the Company recently installed asecond computer- controlled production line for Zila(R) ToloniumChloride, the active ingredient in the OraTest product. "Zila isincreasing production by a factor of five in order to meetincreasing demand for Zila Tolonium Chloride," said Dr. Burkett,who also manages tolonium chloride research and development. Zilais working with researchers at the University of Chicago Schoolof Medicine who are exploring the use of Zila Tolonium Chloridein diagnosing cancerous and pre-cancerous lesions in theesophagus, colon and rectum.

This document contains forward-looking statements within themeaning of Section 27A of the Securities Act of 1933 and Section21E of the Securities Exchange Act of 1934. These forward-lookingstatements are based largely on Zila's expectations or forecastsof future events, can be affected by inaccurate assumptions andare subject to various business risks and known and unknownuncertainties, a number of which are beyond the Company'scontrol. These include possible political, economic orcontractual complications involved in foreign business dealings.Therefore, actual results could differ materially from theforward-looking statements contained herein. A wide variety offactors could cause or contribute to such differences and couldadversely impact revenues, profitability, cash flows and capitalneeds. There can be no assurance that the forward-lookingstatements contained in this document will, in fact, transpire orprove to be accurate. For a more detailed description of theseand other cautionary factors that may affect Zila's futureresults, please refer to Zila's annual report on Form 10-K forits fiscal year ended July 31, 1998, filed with the Securitiesand Exchange Commission. ots Original Text Service: Zila, Inc.Internet: http://www.newsaktuell.de Contact: Adrian Webber ofZila Europe, 01722 412312

Subscribers please note that material bearing the slug"PROTEXT" is not part of CTK's news service and is not to bepublished under the "CTK" slug. Protext is a commercial serviceproviding distribution of press releases from clients, who areidentified in the text of Protext reports and who bear fullresponsibility for their contents.

PROTEXT